Gd2 binding molecule
AssigneeMie University
InventorsHiroshi SHIKU, Yasushi AKAHORI, Hiroshi MIWA, Hiroshi FUJIWARA, Koichi FURUKAWA, Keiko FURUKAWA, Yuhsuke OHMI
Life of this patent
Estimating the term…
Loading patent…
AssigneeMie University
InventorsHiroshi SHIKU, Yasushi AKAHORI, Hiroshi MIWA, Hiroshi FUJIWARA, Koichi FURUKAWA, Keiko FURUKAWA, Yuhsuke OHMI
Estimating the term…
Provided is a cancer treatment or prevention technique that molecularly targets GD2. A GD2-binding molecule includes a heavy-chain variable region containing a heavy-chain CDR1 containing the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 containing the amino acid sequence represented by SEQ ID NO: 2, and a heavy-chain CDR3 containing the amino acid sequence represented by SEQ ID NO: 3, and/or a light-chain variable region containing a light-chain CDR1 containing the amino acid sequence represented by SEQ ID NO: 9, a light-chain CDR2 containing the amino acid sequence represented by SEQ ID NO: 10, and a light-chain CDR3 containing the amino acid sequence represented by SEQ ID NO: 11.
A chimeric antigen receptor comprising a GD2-binding domain comprising
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.